Early detection of prostate cancer: AUA guideline

H. Ballentine Carter, Peter C. Albertsen, Michael J. Barry, Ruth Etzioni, Stephen J. Freedland, Kirsten Lynn Greene, Lars Holmberg, Philip Kantoff, Badrinath R. Konety, Mohammad Hassan Murad, David F. Penson, Anthony L. Zietman

Research output: Contribution to journalArticle

565 Citations (Scopus)

Abstract

Purpose: The guideline purpose is to provide the urologist with a framework for the early detection of prostate cancer in asymptomatic average risk men. Materials and Methods: A systematic review was conducted and summarized evidence derived from over 300 studies that addressed the predefined outcomes of interest (prostate cancer incidence/mortality, quality of life, diagnostic accuracy and harms of testing). In addition to the quality of evidence, the panel considered values and preferences expressed in a clinical setting (patient-physician dyad) rather than having a public health perspective. Guideline statements were organized by age group in years (age <40; 40 to 54; 55 to 69; ≥70). Results: Except prostate specific antigen-based prostate cancer screening, there was minimal evidence to assess the outcomes of interest for other tests. The quality of evidence for the benefits of screening was moderate, and evidence for harm was high for men age 55 to 69 years. For men outside this age range, evidence was lacking for benefit, but the harms of screening, including over diagnosis and overtreatment, remained. Modeled data suggested that a screening interval of two years or more may be preferred to reduce the harms of screening. Conclusions: The Panel recommended shared decision-making for men age 55 to 69 years considering PSA-based screening, a target age group for whom benefits may outweigh harms. Outside this age range, PSA-based screening as a routine could not be recommended based on the available evidence. The entire guideline is available at www.AUAnet.org/education/ guidelines/prostate-cancer-detection.cfm.

Original languageEnglish (US)
Pages (from-to)419-426
Number of pages8
JournalJournal of Urology
Volume190
Issue number2
DOIs
StatePublished - Aug 1 2013
Externally publishedYes

Fingerprint

Early Detection of Cancer
Prostatic Neoplasms
Guidelines
Age Groups
Prostate-Specific Antigen
Decision Making
Public Health
Quality of Life
Physicians
Education
Mortality
Incidence

Keywords

  • early detection of cancer
  • prostate-specific antigen
  • prostatic neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Carter, H. B., Albertsen, P. C., Barry, M. J., Etzioni, R., Freedland, S. J., Greene, K. L., ... Zietman, A. L. (2013). Early detection of prostate cancer: AUA guideline. Journal of Urology, 190(2), 419-426. https://doi.org/10.1016/j.juro.2013.04.119

Early detection of prostate cancer : AUA guideline. / Carter, H. Ballentine; Albertsen, Peter C.; Barry, Michael J.; Etzioni, Ruth; Freedland, Stephen J.; Greene, Kirsten Lynn; Holmberg, Lars; Kantoff, Philip; Konety, Badrinath R.; Murad, Mohammad Hassan; Penson, David F.; Zietman, Anthony L.

In: Journal of Urology, Vol. 190, No. 2, 01.08.2013, p. 419-426.

Research output: Contribution to journalArticle

Carter, HB, Albertsen, PC, Barry, MJ, Etzioni, R, Freedland, SJ, Greene, KL, Holmberg, L, Kantoff, P, Konety, BR, Murad, MH, Penson, DF & Zietman, AL 2013, 'Early detection of prostate cancer: AUA guideline', Journal of Urology, vol. 190, no. 2, pp. 419-426. https://doi.org/10.1016/j.juro.2013.04.119
Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL et al. Early detection of prostate cancer: AUA guideline. Journal of Urology. 2013 Aug 1;190(2):419-426. https://doi.org/10.1016/j.juro.2013.04.119
Carter, H. Ballentine ; Albertsen, Peter C. ; Barry, Michael J. ; Etzioni, Ruth ; Freedland, Stephen J. ; Greene, Kirsten Lynn ; Holmberg, Lars ; Kantoff, Philip ; Konety, Badrinath R. ; Murad, Mohammad Hassan ; Penson, David F. ; Zietman, Anthony L. / Early detection of prostate cancer : AUA guideline. In: Journal of Urology. 2013 ; Vol. 190, No. 2. pp. 419-426.
@article{56b61b350f7f47069b611da3b49fc6ca,
title = "Early detection of prostate cancer: AUA guideline",
abstract = "Purpose: The guideline purpose is to provide the urologist with a framework for the early detection of prostate cancer in asymptomatic average risk men. Materials and Methods: A systematic review was conducted and summarized evidence derived from over 300 studies that addressed the predefined outcomes of interest (prostate cancer incidence/mortality, quality of life, diagnostic accuracy and harms of testing). In addition to the quality of evidence, the panel considered values and preferences expressed in a clinical setting (patient-physician dyad) rather than having a public health perspective. Guideline statements were organized by age group in years (age <40; 40 to 54; 55 to 69; ≥70). Results: Except prostate specific antigen-based prostate cancer screening, there was minimal evidence to assess the outcomes of interest for other tests. The quality of evidence for the benefits of screening was moderate, and evidence for harm was high for men age 55 to 69 years. For men outside this age range, evidence was lacking for benefit, but the harms of screening, including over diagnosis and overtreatment, remained. Modeled data suggested that a screening interval of two years or more may be preferred to reduce the harms of screening. Conclusions: The Panel recommended shared decision-making for men age 55 to 69 years considering PSA-based screening, a target age group for whom benefits may outweigh harms. Outside this age range, PSA-based screening as a routine could not be recommended based on the available evidence. The entire guideline is available at www.AUAnet.org/education/ guidelines/prostate-cancer-detection.cfm.",
keywords = "early detection of cancer, prostate-specific antigen, prostatic neoplasms",
author = "Carter, {H. Ballentine} and Albertsen, {Peter C.} and Barry, {Michael J.} and Ruth Etzioni and Freedland, {Stephen J.} and Greene, {Kirsten Lynn} and Lars Holmberg and Philip Kantoff and Konety, {Badrinath R.} and Murad, {Mohammad Hassan} and Penson, {David F.} and Zietman, {Anthony L.}",
year = "2013",
month = "8",
day = "1",
doi = "10.1016/j.juro.2013.04.119",
language = "English (US)",
volume = "190",
pages = "419--426",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Early detection of prostate cancer

T2 - AUA guideline

AU - Carter, H. Ballentine

AU - Albertsen, Peter C.

AU - Barry, Michael J.

AU - Etzioni, Ruth

AU - Freedland, Stephen J.

AU - Greene, Kirsten Lynn

AU - Holmberg, Lars

AU - Kantoff, Philip

AU - Konety, Badrinath R.

AU - Murad, Mohammad Hassan

AU - Penson, David F.

AU - Zietman, Anthony L.

PY - 2013/8/1

Y1 - 2013/8/1

N2 - Purpose: The guideline purpose is to provide the urologist with a framework for the early detection of prostate cancer in asymptomatic average risk men. Materials and Methods: A systematic review was conducted and summarized evidence derived from over 300 studies that addressed the predefined outcomes of interest (prostate cancer incidence/mortality, quality of life, diagnostic accuracy and harms of testing). In addition to the quality of evidence, the panel considered values and preferences expressed in a clinical setting (patient-physician dyad) rather than having a public health perspective. Guideline statements were organized by age group in years (age <40; 40 to 54; 55 to 69; ≥70). Results: Except prostate specific antigen-based prostate cancer screening, there was minimal evidence to assess the outcomes of interest for other tests. The quality of evidence for the benefits of screening was moderate, and evidence for harm was high for men age 55 to 69 years. For men outside this age range, evidence was lacking for benefit, but the harms of screening, including over diagnosis and overtreatment, remained. Modeled data suggested that a screening interval of two years or more may be preferred to reduce the harms of screening. Conclusions: The Panel recommended shared decision-making for men age 55 to 69 years considering PSA-based screening, a target age group for whom benefits may outweigh harms. Outside this age range, PSA-based screening as a routine could not be recommended based on the available evidence. The entire guideline is available at www.AUAnet.org/education/ guidelines/prostate-cancer-detection.cfm.

AB - Purpose: The guideline purpose is to provide the urologist with a framework for the early detection of prostate cancer in asymptomatic average risk men. Materials and Methods: A systematic review was conducted and summarized evidence derived from over 300 studies that addressed the predefined outcomes of interest (prostate cancer incidence/mortality, quality of life, diagnostic accuracy and harms of testing). In addition to the quality of evidence, the panel considered values and preferences expressed in a clinical setting (patient-physician dyad) rather than having a public health perspective. Guideline statements were organized by age group in years (age <40; 40 to 54; 55 to 69; ≥70). Results: Except prostate specific antigen-based prostate cancer screening, there was minimal evidence to assess the outcomes of interest for other tests. The quality of evidence for the benefits of screening was moderate, and evidence for harm was high for men age 55 to 69 years. For men outside this age range, evidence was lacking for benefit, but the harms of screening, including over diagnosis and overtreatment, remained. Modeled data suggested that a screening interval of two years or more may be preferred to reduce the harms of screening. Conclusions: The Panel recommended shared decision-making for men age 55 to 69 years considering PSA-based screening, a target age group for whom benefits may outweigh harms. Outside this age range, PSA-based screening as a routine could not be recommended based on the available evidence. The entire guideline is available at www.AUAnet.org/education/ guidelines/prostate-cancer-detection.cfm.

KW - early detection of cancer

KW - prostate-specific antigen

KW - prostatic neoplasms

UR - http://www.scopus.com/inward/record.url?scp=84880005911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880005911&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2013.04.119

DO - 10.1016/j.juro.2013.04.119

M3 - Article

C2 - 23659877

AN - SCOPUS:84880005911

VL - 190

SP - 419

EP - 426

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 2

ER -